MedPath

Development of Novel Gastric Cancer Screening and Diagnosis Technologies Using Tongue Imaging and Study of Tongue Image Changes Mechanisms

Recruiting
Conditions
Tongue Images
Gastric Cancer
Diagnosis
Registration Number
NCT06078930
Lead Sponsor
Zhejiang Cancer Hospital
Brief Summary

In this study, the investigators will prospectively recruit 100,000 individuals, including gastric cancer patients who have not undergone any anti-tumor treatment and non-gastric cancer participants. The investigators will construct a diagnostic model for malignant tumors based on the combination of tongue imaging, tongue coating, saliva, gastric juice, and fecal multi-omics data (including metagenomics, proteomics, metabolomics, etc.). Additionally, the study will explore the relationship between oral, gastric, and intestinal microbiota and the development of malignant tumors.

Detailed Description

Patients with gastric cancer were recruited through outpatient clinics, endoscopy units, and inpatient departments of various centers, with all patients requiring a histopathological diagnosis. Non-gastric cancer participants were sourced from community health check-ups, outpatient clinics, and endoscopy units affiliated with these centers.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
100000
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The differences in tongue images, tongue coating, saliva, gastric juice, and fecal samples between patients with gastric cancer and healthy individuals will be systematically analyzed.5 years
The differences of the clinical information between patients with gastric cancer and healthy participants.5 years

These data of gastric cancer group included age, sex, height, weight, family history, smoking, drinking, TNM staging, tumor location, tumor size, pathological type, grade of differentiation, expression of Her2, nerve invasion, vascular tumor thrombus, lauren type and and blood tumour markers, and these data of healthy participants group included age, sex, height, weight, smoking, drinking and blood tumour markers.

Overall Survival (OS)5 years
Secondary Outcome Measures
NameTimeMethod
Disease Free Survival (DFS)5 years

Trial Locations

Locations (1)

Zhejiang Cancer Hospital

🇨🇳

Hangzhou, Zhejiang, China

Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China
Cheng Xiangdong, MD
Contact
+0086-571-88128041
Chengxd516@126.com
Zhiyuan Xu
Contact
0086-571-88128041
getfar@foxmai.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.